2024 Targeted Therapies for Lung Cancer (TTLC) - Abstracts & Posters-PP01.11 Lee

PP01.11 Lee - Poster

Pdf Summary

This study on patients with relapsed small cell lung cancer (SCLC) aimed to evaluate the prognostic value of early changes in circulating tumor DNA (ctDNA) in predicting progression free survival (PFS) and overall survival (OS). Ninety-five peripheral blood samples from 20 unique patients with relapsed SCLC were analyzed. Patients whose ctDNA cleared on the first on-treatment sample showed improved median PFS (5.2 vs. 1.8 months) and OS (7.4 vs. 3.7 months) compared to those whose ctDNA did not clear. Additionally, patients with a 50% reduction in peak ctDNA variant allele frequency (VAF) had better PFS (3.3 vs. 1.6 months) but not significantly different OS. The study suggests that early changes in ctDNA can help predict clinical outcomes and guide therapeutic decisions for chemo-resistant patients. The findings highlight the importance of monitoring ctDNA dynamics in patients with relapsed SCLC for improved treatment efficacy and potentially identifying therapeutic opportunities. The references provided in the study support the relevance and validity of the study's methodology and results.

Keywords

small cell lung cancer

ctDNA

circulating tumor DNA

progression free survival

overall survival

chemo-resistant patients

variant allele frequency

therapeutic decisions

monitoring ctDNA dynamics

relapsed SCLC